German pharmaceutical and chemical company AG buys U.S. manufacturer of vitamins and nutritional supplements Schiff Nutrition International Inc.. $ 1.2 billion. The company simultaneously announced that its net profit in the third quarter due to extraordinary items fell by 17.8 percent to 528 million euros.New acquisitions to strengthen our activities in the non prescription drugs that are very unstable business. Many pharmaceutical companies are looking to expand its range of products that are not prescribed. This area is less profitable, but prescription drugs are high-risk categories, especially if awry clinical trials of new drugs or drug patent protection ends. offers Schiff per share $ 34, which compared to Friday’s closing price of shares on the stock exchange in a profit of 47 percent. The transaction should be completed later this year. Bayer Revenues in the quarter rose by 11.4 percent to 9.665 billion euros. Refined EBITDA rose by 2.2 percent to β¬ 1.85 billion, which was roughly in line with analysts’ estimates. Growth division of prescription drugs compared to weaker performance in the plastics division. The company was forced in the third quarter accounted for including β¬ 205 million due to a dispute associated with contraceptive Yasmin, or Yaz, which has lead to blood clots. Due to the restructuring of the company recorded exceptional costs 134 million euros, penned by AP and Reuters. is the largest German producer of medicines, known among other things due to aspirin. However, it also produces equipment for weed, chemicals and plastics.
The company is the second largest producer of plastics in the world and the second largest agrochemical company. MaterialScience division is the world’s largest manufacturer of padding and insulation foams and plastics used in the manufacture of sports goggles, DVDs and automotive lighting.